Researchers at the University of Michigan Health Rogel Cancer Center have uncovered a key reason why a typically normal protein goes awry and fuels cancer.
They found the protein NSD2 alters the function of the androgen receptor, an important regulator of normal prostate development. When androgen receptor binds with NSD2, it causes rapid cell division and growth leading to prostate cancer. The study, published in Nature Genetics, may suggest a new way to therapeutically target prostate cancer. The findings illuminate a phenomenon not previously understood.
With the passage of the 21st Century Cures Act in 2021, patients were granted access to their medical test results without delay—often before their physician can review them. Pathology reports aren’t written with patients as a target audience and they contain complex medical terminology which can often lead to patient confusion and anxiety. To address this, researchers led by Cathryn Lapedis, M.D., M.P.H., of the Department of Pathology at Michigan Medicine, recently examined how a pathology explanation clinic, or PEC, could improve the experience of a small group of patients newly diagnosed with prostate cancer.
In a manuscript published this week in JAMA Oncology, senior author Dr. Arul Chinnaiyan and members of the EDRN-PCA3 Study Group reported on their development and validation of a new 18-gene urine-based test for diagnosis of high-grade prostate cancer, MPS2. This test was initially developed in the Department of Pathology.
Physician Scientist Dr. Aaron Udager shares his journey.
Dr. Arul Chinnaiyan, S. P. Hicks Endowed Professor of Pathology and Professor of Urology at Michigan Medicine Department of Pathology and Director of the Michigan Center for Translational Pathology, was recently recognized for his outstanding achievements by the American Association of Cancer Research. He was presented with the AACR James S. Ewing-Thelma B. Dunn Award for Outstanding Achievement in Pathology in Cancer Research award at the 2023 AACR Annual Meeting. Please join us in congratulating Dr. Arul Chinnaiyan for this well-deserved prestigious honor!
The University of Michigan Rogel Cancer Center researchers received one of the Prostate Cancer Foundation’s four inaugural Class of 2022 TACTICAL (Therapy ACceleration To Intercept Cancer Lethality) Award. This $30 million program will support cross-disciplinary pioneering research toward the goal of developing 21st Century therapies for the most life-threatening form of prostate cancer [...]
A research team from the Michigan Center for Translational Pathology undertook a study to illustrate how careful assessment of cytologic and biomarker features may provide physicians with information on Metastatic Prostatic Cancer (MCP) patients’ prognosis and the best therapies to consider [...]
The role of artificial intelligence (AI) in healthcare continues to expand. In a recent issue of BMC Cancer, Dr. Vipulkumar Dadhania (first author) and colleagues published a result of their study Leveraging artificial intelligence to predict ERG gene fusion status in prostate cancer. The expert team from the Michigan Center for Translational Pathology developed a deep-learning-based model to predict ERG genomic rearrangements in prostatic adenocarcinomas using only H&E-stained digital slides [...]
A chromatin degrader stops transcription factors from driving cancer, which may serve as a potential treatment approach for over 90% of prostate cancers.
Andi Cani, PhD, successfully defended his thesis entitled “Precision Medicine Approaches to Hormone-Driven Cancer” on December 5, 2019. [...]
Every year in the United States, nearly 3 million men hear the words, “You have prostate cancer.” That is 1 in 9 men each year. The word “cancer” triggers an immediate response in most people…fear, worry about family, denial, and often an increased awareness of one’s mortality. [...]